Article
Biochemistry & Molecular Biology
Chunying Xiao, Zhongbin Sun, Jixin Gao, Yaxing Bai, Chen Zhang, Bingyu Pang, Hongjiang Qiao, Meng Fu, Erle Dang, Gang Wang
Summary: This study demonstrated the critical role of skin barrier protein FLG in the pathogenesis of atopic dermatitis, with CPT-induced dermatitis being more severe in Flg(-/-) mice compared to wild-type mice. Additionally, emollients MPS and ceramide partially restored epidermal function and alleviated skin inflammation in the Flg(-/-) mouse model of AD induced by CPT.
Review
Dermatology
Thomas Luger, Masayuki Amagai, Brigitte Dreno, Marie-Ange Dagnelie, Wilson Liao, Kenji Kabashima, Tamara Schikowski, Ehrhardt Proksch, Peter M. Elias, Michel Simon, Eric Simpson, Erin Grinich, Matthias Schmuth
Summary: AD is a chronic inflammatory skin disorder characterized by eczematous and pruritic skin lesions, with increasing prevalence worldwide in recent decades. Studies have shown that genetic defects affecting structural proteins of the skin barrier, as well as exposure to environmental allergens and pollutants, contribute to the development of AD. Research on epidermal barrier function, inflammation, lipid metabolism, and bacterial communities is crucial for understanding the complex etiology of AD and developing new therapies.
JOURNAL OF DERMATOLOGICAL SCIENCE
(2021)
Article
Allergy
Naoki Okada, Yoshiro Yamamoto, Tsuyoshi Oguma, Jun Tanaka, Katsuyoshi Tomomatsu, Yoshiki Shiraishi, Hiroto Matsuse, Terufumi Shimoda, Hirokazu Kimura, Kentaro Watai, Toshiyuki Harada, Yuka Fujita, Yasushi Obase, Maho Suzukawa, Junko Suzuki, Noboru Takayanagi, Takashi Ishiguro, Katsunori Masaki, Koichi Fukunaga, Koichiro Asano
Summary: This study aimed to explore the essential components in the pathogenesis of allergic bronchopulmonary aspergillosis (ABPA). ABPA was classified into three groups based on the type of preceding asthma, and three components (allergic, eosinophilic, and fungal) were identified. The eosinophilic component was considered as the cardinal feature of ABPA regardless of the presence of preceding asthma or atopic predisposition.
Review
Immunology
Yutaka Hatano, Peter M. Elias
Summary: Permeability barrier disruption can lead to immunological alterations, while inflammatory and immunological mechanisms can interrupt permeability barrier homeostasis. Changes in keratinocytes can cause both barrier dysfunction and immunological alterations, which are referred to as the intrinsic pathogenic mechanism. Molecules and pathways involved in this mechanism are important for disease pathogenesis and potential therapeutic targets for inflammatory cutaneous diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Petra Pavel, Stefan Blunder, Verena Moosbrugger-Martinz, Peter M. Elias, Sandrine Dubrac
Summary: Atopic dermatitis is a chronic inflammatory skin disease influenced by both genetic and environmental factors. Alterations of the epidermal barrier and lipid abnormalities play crucial roles in the development and inflammation of the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Dermatology
Takeshi Nakahara, Makiko Kido-Nakahara, Gaku Tsuji, Masutaka Furue
Summary: Atopic dermatitis is a chronic inflammatory skin disease characterized by skin barrier dysfunction, inflammation, and intense itch. The pathophysiology involves abnormalities in filaggrin, intercellular lipids, and tight junctions leading to skin inflammation and itch.
JOURNAL OF DERMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Nahoko Zeze, Makiko Kido-Nakahara, Gaku Tsuji, Eriko Maehara, Yuki Sato, Sawako Sakai, Kei Fujishima, Akiko Hashimoto-Hachiya, Masutaka Furue, Takeshi Nakahara
Summary: Atopic dermatitis is a skin disorder characterized by inflammation, barrier disruption, and intense itch. This study investigates the involvement of the extracellular signal-regulated kinase (ERK) pathway in the pathogenesis of atopic dermatitis. The results suggest that the ERK pathway plays a role in the development of atopic dermatitis and may be a potential therapeutic target.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Allergy
Jessica W. Hui-Beckman, Elena Goleva, Evgeny Berdyshev, Donald Y. M. Leung
Summary: Atopic dermatitis (AD) and food allergy (FA) are closely related and one-third of AD children develop concomitant FA. Epithelial barrier dysfunction is important in both diseases. Genetic factors such as filaggrin mutations and IL-4 receptor alpha chain polymorphisms are associated with increased risk. In addition, several environmental exposures lead to reduced filaggrin and contribute to skin barrier dysfunction. Staphylococcus aureus colonization appears to contribute to AD and FA as well as activating the type 2 immune response. Comprehensive multiomic studies have identified distinct atopic endotypes with unique characteristics, providing an opportunity for improved diagnosis and prevention of atopy.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Pei-Chin Chen, Yi-Hao Lo, Shi-Ying Huang, Hsin-Lu Liu, Zhi-Kang Yao, Chi- Chang, Zhi-Hong Wen
Summary: This study demonstrated that the ethyl acetate fraction of S. suiae sp. extract has anti-inflammatory effects, alleviates symptoms of AD, inhibits inflammatory responses in skin tissues, and restores barrier function.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
(2022)
Article
Immunology
Hyang Jeon, Geunyeong Kim, Ayesha Kashif, Min Hwa Hong, Ji-Sook Lee, Yujin Hong, Beom Seok Park, Eun Ju Yang, In Sik Kim
Summary: Atopic dermatitis is a chronic disease characterized by skin inflammation and barrier dysfunction, with house dust mites being key allergens. A study on Der p 38, a novel mite allergen, has shown that it triggers atopic dermatitis by reducing skin barrier proteins and increasing inflammatory cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Allergy
Chih-Yung Chiu, Gigin Lin, Chia-Jung Wang, Shuen-Iu Hung, Wen-Hung Chung
Summary: This study identified a correlation between metabolomic profiles in AD patients with FLG mutations and allergic responses, revealing metabolic pathways associated with AD such as nitrogen and amino acid metabolism, microbe-related methane and propanoate metabolism. FLG mutations were positively correlated with total serum IgE levels, with microbial-derived metabolites like dimethylamine and isopropanol strongly associated with methane and propanoate metabolism in AD.
PEDIATRIC ALLERGY AND IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Tubanur Cetinarslan, Lisa Kuemper, Regina Foelster-Holst
Summary: Atopic dermatitis is a common and chronic inflammatory skin disease with various clinical presentations. The etiopathogenesis of AD involves structural and immunological epidermal barrier defect, imbalance of the skin microbiome, genetic background, and environmental factors. Therapeutic options targeting these pathways, such as topical steroids and biological therapies, have gained importance in the treatment of AD.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Review
Medicine, General & Internal
Anna Debinska
Summary: Atopic dermatitis is a common chronic, inflammatory skin disorder with a complex etiology and diverse clinical manifestations. Skin barrier dysfunction and immunological abnormalities play critical roles in its pathogenesis. New therapeutic approaches targeting specific pathophysiological pathways are being developed, emphasizing the regulation of skin barrier-related molecules.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Plant Sciences
Yun-Mi Kang, Hye-Min Kim, Minho Lee, Hyo-Jin An
Summary: The study demonstrates that Echinocystic acid (ECA) improves symptoms of atopic dermatitis (AD) and allergic inflammation by restoring skin barrier, regulating immune balance, and alleviating lung inflammation.
Review
Pharmacology & Pharmacy
Pier Giorgio Puzzovio, Francesca Levi-Schaffer
Summary: The understanding of the pathologic mechanisms of asthma and atopic dermatitis has improved in recent years. However, the high heterogeneity of both diseases complicates diagnosis and treatment, with current strategies mainly focusing on symptom control rather than full healing. There is a need for more personalized approaches to improve diagnosis and treatment efficacy.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Dermatology
Hideki Fujita, Mamitaro Ohtsuki, Akimichi Morita, Ryuji Nagao, Noriko Seko, Kazuko Matsumoto, Yumiko Tani, Tadashi Terui
Summary: The fully human monoclonal antibody secukinumab has shown safety and effectiveness in treating moderate to severe psoriasis and psoriatic arthritis in a 52-week study with a broad range of patients, including those who had previously received biologics. Common adverse reactions included oral candidiasis, with significant improvements in both Psoriasis Area and Severity Index scores and Dermatology Life Quality Index scores observed.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Koremasa Hayama, Hideki Fujita, Keiji Iwatsuki, Tadashi Terui
Summary: This study investigated the quality of life of Japanese GPP patients and compared it with data from a decade ago. While the present patients still experienced significant impairment in quality of life compared to the standard Japanese population, there was noticeable improvement in certain areas, possibly due to advancements in treatment.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Natsumi Ikumi, Hideki Fujita, Tadashi Terui
Summary: Guselkumab treatment for PAO patients showed significant effectiveness in clinical practice, reducing pain and improving arthritis activity index, indicating potential therapeutic value for refractory PAO.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Akimichi Morita, Hidetoshi Takahashi, Kentaro Ozawa, Shinichi Imafuku, Nakama Takekuni, Kenzo Takahashi, Takashi Matsuyama, Yukari Okubo, Yiwei Zhao, Susumu Kitamura, Keiko Takei, Masayuki Yokoyama, Nobukazu Hayashi, Tadashi Terui
Summary: This study demonstrated that long-term ADA treatment is effective and well tolerated in Japanese patients with moderate to severe HS, with a HiSCR achievement rate of 86.7% at 12 weeks and sustained through 52 weeks. Improvements in various secondary endpoints were seen after 12 weeks of treatment and maintained through 52 weeks.
JOURNAL OF DERMATOLOGY
(2021)
Article
Allergy
Shota Toyoshima, Tomomi Sakamoto-Sasaki, Yusuke Kurosawa, Koremasa Hayama, Akira Matsuda, Yasuo Watanabe, Tadashi Terui, Yasuhiro Gon, Kenji Matsumoto, Yoshimichi Okayama
Summary: The study revealed that EVs derived from MCs can activate ILC2s through miR103a-3p, leading to increased production of IL-5 and exacerbating eosinophilic allergic inflammation.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Letter
Dermatology
Maho Nishimura-Tagui, Koremasa Hayama, Hideki Fujita, Yuji Miyamoto, Norihisa Ishii, Tadashi Terui
JOURNAL OF DERMATOLOGY
(2021)
Letter
Dermatology
Y. Niwa, K. Hayama, S. Izaki, H. Koga, N. Ishii, T. Terui, H. Fujita
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2021)
Article
Dermatology
Yukari Okubo, Hitomi Morishima, Richuan Zheng, Tadashi Terui
Summary: The study demonstrated that guselkumab has sustained efficacy and safety in Japanese PPP patients, improving health-related quality of life, with similar effectiveness before W84.
JOURNAL OF DERMATOLOGY
(2021)
Letter
Dermatology
Natsumi Ikumi, Koremasa Hayama, Tadashi Terui, Noboru Kitamura, Masami Takei, Hideki Fujita
JOURNAL OF DERMATOLOGY
(2021)
Editorial Material
Dermatology
Koremasa Hayama, Hideki Fujita, Takashi Hashimoto, Tadashi Terui
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Dermatology
Nobukazu Hayashi, Koremasa Hayama, Kenzo Takahashi, Ichiro Kurokawa, Masateru Okazaki, Tomoko Kashiwagi, Eri Iwashita, Tadashi Terui
Summary: The study evaluated the safety and effectiveness of adalimumab in routine clinical practice in Japan, with 57.4% of patients achieving HiSCR at week 12.
JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Hidehisa Saeki, Yuichiro Tsunemi, Satoru Arai, Susumu Ichiyama, Norito Katoh, Katsuko Kikuchi, Akiharu Kubo, Tadashi Terui, Takeshi Nakahara, Masaki Futamura, Hiroyuki Murota, Atsuyuki Igarashi
Summary: This guideline focuses on defining skin symptoms that require treatment with medical moisturizers for patients with asteatosis. Moisturizers are recommended as the first-line treatment for asteatosis, even in the absence of pruritus if marked scaling or scratch marks are present. The recommendations are based on a balance between the benefits and harm of medical interventions by evaluating previous clinical research reports.
JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
Koremasa Hayama, Hideki Fujita, Tadashi Terui
JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Shigetoshi Sano, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Masafumi Yaguchi, Natsuka Uehara, Takahiro Handa, Masayuki Tanaka, Wendy Zhang, Maria Paris, Masamoto Murakami
Summary: This study evaluated the efficacy and safety of apremilast for Japanese patients with PPP. The results showed that apremilast significantly improved disease severity and patient-reported symptoms, with sustained effectiveness up to week 32. However, there were some adverse events such as diarrhea, abdominal discomfort, headache, and nausea.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2023)
Letter
Dermatology
Keisuke Shimizu, Hideki Fujita, Daisuke Fujisawa, Koremasa Hayama, Satomi Aoki, Akiharu Kubo, Tadashi Terui
JOURNAL OF DERMATOLOGY
(2023)
